Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 27;11(9):1551.
doi: 10.3390/diagnostics11091551.

MRI and Targeted Biopsy Essential Tools for an Accurate Diagnosis and Treatment Decision Making in Prostate Cancer

Suraj Samtani  1   2 , Mauricio Burotto  1   3 , Juan Carlos Roman  4   5 , Daniela Cortes-Herrera  4 , Annerleim Walton-Diaz  4   5   6
Affiliations
Review

MRI and Targeted Biopsy Essential Tools for an Accurate Diagnosis and Treatment Decision Making in Prostate Cancer

Suraj Samtani et al. Diagnostics (Basel). .

Abstract

Prostate cancer (PCa) is one of the most frequent causes of cancer death worldwide. Historically, diagnosis was based on physical examination, transrectal (TRUS) images, and TRUS biopsy resulting in overdiagnosis and overtreatment. Recently magnetic resonance imaging (MRI) has been identified as an evolving tool in terms of diagnosis, staging, treatment decision, and follow-up. In this review we provide the key studies and concepts of MRI as a promising tool in the diagnosis and management of prostate cancer in the general population and in challenging scenarios, such as anteriorly located lesions, enlarged prostates determining extracapsular extension and seminal vesicle invasion, and prior negative biopsy and the future role of MRI in association with artificial intelligence (AI).

Keywords: MRI; active surveillance; artificial intelligence; diagnosis; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Suraj Samtani, Speaker MSD, Roche, AstraZeneca. Advisory MSD, Roche. Mauricio Burotto, Speaker MSD, Roche, AstraZeneca, BMS, Novartis. Advisory and Consulting: MSD, BMS, Roche.

Similar articles

See all similar articles

Cited by

References

    1. Bray F., Me J.F., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Damadian R. Tumor Detection by Nuclear Magnetic Resonance. Science. 1971;171:1151–1153. doi: 10.1126/science.171.3976.1151. - DOI - PubMed
    1. Steyn J.H., Smith F.W. Nuclear Magnetic Resonance Imaging of the Prostate. BJU Int. 1982;54:726–728. doi: 10.1111/j.1464-410X.1982.tb13634.x. - DOI - PubMed
    1. Narayan P., Jajodia P., Kurhanewicz J., Thomas A., MacDonald J., Hubesch B., Hedgcock M., Anderson C.M., James T.L., Tanagho E.A., et al. Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31phosphorus magnetic resonance spectroscopy: A preliminary report. J. Urol. 1991;146:66–74. doi: 10.1016/S0022-5347(17)37716-9. - DOI - PubMed
    1. Tamada T., Kido A., Takeuchi M., Yamamoto A., Miyaji Y., Kanomata N., Sone T. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer. Eur. J. Radiol. 2019;121:108704. doi: 10.1016/j.ejrad.2019.108704. - DOI - PubMed

LinkOut - more resources